Related Experiment Video

Updated: Aug 7, 2025

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.3K

Vericiguat for the treatment of heart failure with reduced ejection fraction

Ahmed K Siddiqi1, Stephen J Greene2,3, Marat Fudim2,3

  • 1Department of Medicine, Ziauddin Medical University, Karachi, Pakistan.

Expert Review of Cardiovascular Therapy
|March 7, 2023
PubMed

Insights

Vericiguat, a soluble guanylate cyclase stimulator, significantly reduces cardiovascular mortality and heart failure hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF). It offers a favorable safety profile for those with persistent high residual risk.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure with reduced ejection fraction (HFrEF) carries a high residual risk of mortality and hospitalizations despite advancements.
  • Vericiguat is an oral soluble guanylate cyclase (sGC) stimulator approved for symptomatic chronic heart failure (HF) patients post-hospitalization or requiring diuretics.

Purpose of the Study:

  • To review the pharmacology, clinical efficacy, and tolerability of vericiguat in HFrEF.
  • To discuss the role of vericiguat in current clinical practice for HFrEF management.

Main Methods:

  • Review of existing literature on vericiguat's pharmacology, efficacy, and safety.
  • Analysis of data from the VICTORIA trial regarding vericiguat's impact on cardiovascular outcomes and patient adherence.

Main Results:

  • Vericiguat demonstrated an absolute event-rate reduction of 4.2 events per 100 patient-years for cardiovascular mortality or HF hospitalizations.
  • High adherence (nearly 90%) to vericiguat 10 mg was observed in the VICTORIA trial, with a favorable tolerability and safety profile.

Conclusions:

  • Vericiguat effectively reduces the risk of cardiovascular mortality and HF hospitalizations in HFrEF patients.
  • Given the persistent high residual risk in HFrEF, vericiguat plays a crucial role in improving outcomes for patients with worsening symptoms.
Abstract

Keywords:
HFrEFHeart failurecardiovascular deathheart failure with reduced ejection fractionhospitalizationsoluble guanylate cyclase stimulatorvericiguat

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K
Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

8.9K

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
18
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
435
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
660
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
479
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
411
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
212